This content is not available in your region

Japan's Kowa says ivermectin showed 'antiviral effect' against Omicron in research

Access to the comments Comments
By Reuters

TOKYO – Japanese trading and pharmaceutical company Kowa Co Ltd said on Monday anti-parasite drug ivermectin showed an “antiviral effect” against Omicron and other variants of coronavirus in joint non-clinical research.

The company did not provide further details.

The firm has been working with Kitasato University, a medical university in Tokyo, on testing the drug which is used to treat parasites in animals and humans, as a potential treatment for COVID-19.

Clinical trials are ongoing but promotion of the drug as a COVID-19 treatment has generated controversy.

The drug is not approved for treatment of COVID-19 in Japan and the U.S. Federal Drug Administration, the World Health Organization and the EU drug regulator have warned against its use.